SCHEMBL10157352

SCHEMBL10157352

CCCCOC(=O)Nc1ccc(OC)c(C2CCN(C3CCN(C)CC3)CC2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.45
NPC1 O15118 8/20 0.45
SMN1; SMN2 Q16637 8/20 0.45
HPGD P15428 5/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
MAPT P10636 4/20 0.44
KMT2A Q03164 2/20 0.44
TP53 P04637 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
EHMT2 Q96KQ7 1/20 0.44
CASP1 P29466 1/20 0.43
ALDH1A1 P00352 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
LMNA P02545 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL328215 0.93 RAB9A (0.45) RAB9ANPC1SMN1; SMN2HPGDCYP1A2
SCHEMBL10157334 0.86 RAB9A (0.50) RAB9ANPC1SMN1; SMN2HPGDCYP1A2
SCHEMBL10157306 0.83 NPC1 (0.52) RAB9ANPC1SMN1; SMN2HPGDCYP1A2
SCHEMBL10156819 0.82 RAB9A (0.51) RAB9ANPC1SMN1; SMN2HPGDCYP1A2
SCHEMBL17690622 0.81 RAB9A (0.48) RAB9ANPC1SMN1; SMN2HPGDCYP1A2
SCHEMBL328248 0.81 RAB9A (0.48) RAB9ANPC1SMN1; SMN2HPGDCYP1A2
SCHEMBL328326 0.81 PDE4B (0.49) RAB9ANPC1SMN1; SMN2HPGDCYP1A2
SCHEMBL17689758 0.77 EHMT2 (0.53) EHMT2
SCHEMBL10156184 0.75 RAB9A (0.57) RAB9ANPC1SMN1; SMN2HPGDCYP1A2
SCHEMBL10036157 0.74 HTT (0.41) SMN1; SMN2MAPTKMT2AEHMT2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 RAB9A 1850/4885NPC1 3728/4885SMN1; SMN2 4467/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 RAB9A 1850/4885NPC1 3728/4885SMN1; SMN2 4467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.